Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15369785 | 1.00 | FUCA1 (0.33) | FUCA1OGA | |
| SCHEMBL19565361 | 1.00 | FUCA1 (0.33) | FUCA1OGA | |
| SCHEMBL26369274 | 0.93 | FUCA1 (0.32) | FUCA1OGA | |
| SCHEMBL26369256 | 0.93 | FUCA1 (0.32) | FUCA1OGA | |
| SCHEMBL26369286 | 0.93 | FUCA1 (0.32) | FUCA1OGA | |
| SCHEMBL12371022 | 0.93 | FUCA1 (0.32) | FUCA1OGA | |
| SCHEMBL26369295 | 0.93 | FUCA1 (0.32) | FUCA1OGA | |
| SCHEMBL12371038 | 0.93 | FUCA1 (0.32) | FUCA1OGA | |
| SCHEMBL26369280 | 0.93 | FUCA1 (0.32) | FUCA1OGA | |
| SCHEMBL26369259 | 0.93 | FUCA1 (0.32) | FUCA1OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2016-08-04 | — | — | US | disclosed |
| US-20090280567-A1 | STABILIZED SIRNAS AS TRANSFECTION CONTROLS AND SILENCING REAGENTS | DHARMACON, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090197332-A1 | Modified Short Interfering RNA | QIAGEN GMBH (DE) | 2009-08-06 | — | — | US | disclosed |
| US-20070269889-A1 | Stabilized siRNAs as transfection controls and silencing reagents | DHARMACON, INC. (US) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, NTPCR, TYMP | FUCA1 1162/4885OGA 1137/4885 |
| US-20090197332-A1 | Modified Short Interfering RNA | NSUN2, NSUN3, METTL16 | FUCA1 479/4885OGA 333/4885 |
| US-20090280567-A1 | STABILIZED SIRNAS AS TRANSFECTION CONTROLS AND SILENCING REAGENTS | PHAX, NSUN2, UPF1 | FUCA1 523/4885OGA 200/4885 |
| US-20070269889-A1 | Stabilized siRNAs as transfection controls and silencing reagents | PHAX, NSUN2, UPF1 | FUCA1 523/4885OGA 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.